Chris Carthy, Ph.D.
Advisor
chris.carthy@torreyapartners.com
(415) 412-7421
Chris has over a decade of prior healthcare industry experience as a scientist, business development executive and investment banker. He has been involved in numerous equity financings and strategic transactions in the life science sector, including biopharmaceutical, diagnostic, tools and services, and medical device companies. Chris is a former bench scientist and author of 25 scientific publications. He previously worked at Aquilo Partners where he was a Principal and executed numerous equity financings and M&A transactions for life science companies. He began his biotechnology career at QLT as a bench scientist and then joined Affinium Pharmaceuticals, as a business development executive. Chris received his Ph.D. from the University of British Columbia in the Department of Pathology and Laboratory Medicine and his B.Sc. from Queen's University.
Selected Transaction Experience:
• Columbia Labs, Sale of Progesterone Related Assets to Watson, $107.5 million (pending)
• Ikonisys, Partnership of oncoFISH Cervical with Enzo Biochem (2009)
• Nabi Biopharmaceuticals, Sale of PentaStaph to GlaxoSmithKline, $47.5 million (2009)
• DFine, Series C Preferred, Advisor to Investor Group (2008)
• Ore Pharmaceuticals, Divestiture of DioGenix Subsidiary to Nerveda (2008)
• Open Biosystems, Sale to Thermo Fisher (2008)
• Complete Genomics, Series C Preferred (2008)
• Gene Logic, Sale of Genomics Division to Ocimum (2007)
• QuatRx, Series E Preferred, $44 million (2007)
• Epocal, Series C Preferred, $31 million (2007)
• Laboratory Partners, Series B and D Preferred & Debt, $69 million (2007)
• Applied Imaging, Sale to Genetix, $26 million (2006)
• Solstice Neurosciences, Series B Preferred & Debt, $85 million (2006)
• Aerovance, Series C Preferred, $60 million (2006)
• Aerogen, Sale to Nektar, $32 million (2005)
• Quantum Dot, Sale to Invitrogen (2005)
• Cellomics, Sale to Fisher Scientific, $49 million (2005)
• Replidyne, Series D Preferred, $62.5 million (2005)
• Affinium Pharmaceuticals, Acquisition of MRSA Program from GSK (2003)
• Affinium Pharmaceuticals, Discovery Alliance with Pfizer, $30 million (2002)
Chris is a registered representative with Financial West Group, Torreya’s financing partner.
Copyright © 2010 Torreya Partners LLC. All rights reserved.
Securities offered through Financial West Group, member FINRA/SIPC. Torreya Partners LLC and Financial West Group are unaffiliated entities.